Using MxA to guide antiviral treatment for respiratory viral infections
Application of Myxovirus Resistance Protein a in Antiviral Treatment Guidance of Respiratory Viral Infections
This study is testing if using a special protein called MxA to guide antiviral treatment can help people with respiratory viral infections like influenza and COVID-19 recover faster and have fewer repeat infections compared to standard treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Capital Medical University Academic / other |
| Locations | 1 site (Beijing, Beijing) |
| Trial ID | NCT06668025 on ClinicalTrials.gov |
What this trial studies
This pilot randomized controlled trial investigates the effectiveness of Myxovirus Resistance Protein A (MxA)-guided antiviral treatment compared to standard treatment for patients with respiratory viral infections, including influenza and COVID-19. The study aims to determine if using MxA as a biomarker can lead to better clinical outcomes by reducing the recurrence of infections and improving symptom resolution times. Participants will be monitored for 30 days following treatment to assess the impact of the MxA-guided approach on their recovery.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with a primary diagnosis of influenza or COVID-19, who are currently receiving or are planned to receive antiviral treatment.
Not a fit: Patients who are severely ill, such as those requiring mechanical ventilation or with known immunosuppression, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized antiviral treatments for patients with respiratory viral infections.
How similar studies have performed: While the use of biomarkers in guiding antiviral treatment is a novel approach, similar studies have shown promise in improving treatment outcomes for viral infections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * ≥ 18 years old * With a primary diagnosis of influenza or COVID-19 infection, diagnosed by a rapid antigen test or RT-PCR * Duration of infection ≤14 days for non-severe patients and \< 28 days for patients with severe infections * Currently receiving or planned to receive antiviral treatment, with the attending physician yet to decide on the discontinuation of the antiviral treatment Exclusion Criteria: * Current endotracheal intubation and mechanical ventilation * Current vasopressor use * Known immunosuppression * Received interferon therapy within 30 days before screening * Systemic inflammatory responses within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery * Received vaccine in the past 30 days * Active tuberculosis * With contraindications for antiviral treatment * Unable to obtain eligible samples * Co-infected with influenza and COVID-19
Where this trial is running
Beijing, Beijing
- China-Japan Friendship hospital — Beijing, Beijing, China (Recruiting)
Study contacts
- Study coordinator: Yeming Wang, M.D.
- Email: wwyymm_love@163.com
- Phone: +86 84206264
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.